Individualized Surgical Guidance in HCC-BDTT
1 other identifier
observational
151
1 country
1
Brief Summary
The Rboost causal model can identify patients who are most likely to benefit among HCC-BDTT patients. Adherence to the individualized recommendation improves survival. This data-driven tool offers vital support for precision surgical decision-making in this high-risk disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2025
CompletedFirst Submitted
Initial submission to the registry
March 8, 2026
CompletedFirst Posted
Study publicly available on registry
March 19, 2026
CompletedMarch 19, 2026
March 1, 2026
10 months
March 8, 2026
March 16, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Treatment Effects
5-year overall survival (OS)
2025.09.01
Study Arms (2)
Bile Duct Resection (BDR) group
Non-Bile Duct Resection (NBDR) group
Interventions
This group includes biliary/enteric reconstruction, bile duct resection with thrombectomy, and biliary tract interventions
Eligibility Criteria
This dual-center observational study was approved by the Institutional Review Board (IRB) of the First Affiliated Hospital of Sun Yat-sen University (approval number: \[2023\]016), with a waiver of informed consent. This study retrospectively enrolled patients with HCC from two campuses: Yuexiu campus (Center 1; January 2011-August 2020) and Huangpu campus (Center 2; August 2014-August 2020).
You may qualify if:
- Pathologically confirmed HCC with BDTT;
- Absence of extrahepatic malignancies at the time of HCC diagnosis;
- Undergone R0 curative hepatectomy;
- No prior antitumor therapies, such as chemotherapy or immunotherapy, before surgery;
- Availability of preoperative imaging (CT or MRI) with standardized tumor evaluation.
You may not qualify if:
- Pathological findings indicating concurrent cholangiocarcinoma and HCC;
- Loss to follow-up, preventing outcome evaluation, or insufficient clinical data for analysis.
- Significant comorbidities (e.g., severe cardiac or renal failure) that could affect surgical outcomes.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
China, Guangdong
Guangzhou, Guangdong, 510000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
March 8, 2026
First Posted
March 19, 2026
Study Start
August 1, 2024
Primary Completion
June 1, 2025
Study Completion
August 1, 2025
Last Updated
March 19, 2026
Record last verified: 2026-03